Hepatitis Monthly

Published by: Kowsar

An Index to Predict Ribavirin-Induced Anemia in Asian Patients With Chronic Genotype 1 Hepatitis C

Sheng-Hung Chen 1 , 2 , 3 , Cheng-Yuan Peng 2 , 3 , * , Hsueh-Chou Lai 1 , 3 , 4 , Wen-Pang Su 3 , Chia-Hsin Lin 3 , Yu-Fen Li 5 , Po-Heng Chuang 3 and Ching-Hsiang Chen 3
Authors Information
1 Institute of Clinical Medical Science, School of Medicine, China Medical University, Taichung, Taiwan
2 School of Medicine, China Medical University, Taichung, Taiwan
3 Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
4 College of Chinese Medicine, China Medical University, Taichung, Taiwan
5 Institute of Biostatistics, China Medical University, Taichung, Taiwan
Article information
  • Hepatitis Monthly: March 2015, 15 (3); e58834
  • Published Online: March 20, 2015
  • Article Type: Research Article
  • Received: January 22, 2015
  • Revised: February 10, 2015
  • Accepted: February 21, 2015
  • DOI: 10.5812/hepatmon.27148

To Cite: Chen S, Peng C, Lai H, Su W, Lin C, et al. An Index to Predict Ribavirin-Induced Anemia in Asian Patients With Chronic Genotype 1 Hepatitis C, Hepat Mon. 2015 ; 15(3):e58834. doi: 10.5812/hepatmon.27148.

Copyright © 2015, Kowsar Corp.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17(2): 107-15[DOI][PubMed]
  • 2. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007; 106(2): 148-55[DOI][PubMed]
  • 3. Yang JF, Lin CI, Huang JF, Dai CY, Lin WY, Ho CK, et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci. 2010; 26(9): 461-9[DOI][PubMed]
  • 4. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009; 24(3): 336-45[DOI][PubMed]
  • 5. Hung CH, Lee CM, Lu SN, Wang JH, Chen CH, Hu TH, et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int. 2006; 26(9): 1079-86[DOI][PubMed]
  • 6. Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2002; 16(9): 1623-32[PubMed]
  • 7. Inoue Y, Homma M, Matsuzaki Y, Shibata M, Matsumura T, Ito T, et al. Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res. 2006; 34(1): 23-7[DOI][PubMed]
  • 8. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G, Basl Steering Committee . Factors influencing ribavirin-induced hemolysis. J Hepatol. 2001; 34(6): 911-6[PubMed]
  • 9. Hu CC, Weng CH, Lin CL, Tien HC, Kuo YL, Chien CH, et al. Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-alpha. Ren Fail. 2012; 34(4): 429-34[DOI][PubMed]
  • 10. Scherzer TM, Stattermayer AF, Stauber R, Maieron A, Strasser M, Laferl H, et al. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. J Hepatol. 2013; 59(5): 964-71[DOI][PubMed]
  • 11. Birerdinc A, Estep M, Afendy A, Stepanova M, Younossi I, Baranova A, et al. Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C). J Viral Hepat. 2012; 19(6): 414-22[DOI][PubMed]
  • 12. Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, et al. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol. 2011; 83(6): 1048-57[DOI][PubMed]
  • 13. Krishnan SM, Dixit NM. A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms. Antivir Ther. 2012; 17(8): 1581-92[DOI][PubMed]
  • 14. Tsubota A, Shimada N, Abe H, Yoshizawa K, Agata R, Yumoto Y, et al. Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C. World J Gastroenterol. 2012; 18(41): 5879-88[DOI][PubMed]
  • 15. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, et al. Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C. J Med Virol. 2013; 85(3): 449-58[DOI][PubMed]
  • 16. Hsieh MY, Dai CY, Lee LP, Huang JF, Chuang WL, Hou NJ, et al. Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients. Kaohsiung J Med Sci. 2012; 28(2): 86-93[DOI][PubMed]
  • 17. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008; 47(6): 1884-93[DOI][PubMed]
  • 18. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010; 139(4): 1190-7[DOI][PubMed]
  • 19. Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology. 2011; 53(2): 415-21[DOI][PubMed]
  • 20. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology. 2011; 53(1): 7-13[DOI][PubMed]
  • 21. Youden WJ. Index for rating diagnostic tests. Cancer. 1950; 3(1): 32-5[PubMed]
  • 22. Domingo P, Guardiola JM, Salazar J, Torres F, Mateo MG, Pacho C, et al. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. Antimicrob Agents Chemother. 2012; 56(6): 2987-93[DOI][PubMed]
  • 23. Eskesen AN, Melum E, Moghaddam A, Bjoro K, Verbaan H, Ring-Larsen H, et al. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Eur J Gastroenterol Hepatol. 2012; 24(8): 890-6[DOI][PubMed]
  • 24. Naggie S, Rallon NI, Benito JM, Morello J, Rodriguez-Novoa S, Clark PJ, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. J Infect Dis. 2012; 205(3): 376-83[DOI][PubMed]
  • 25. Osinusi A, Naggie S, Poonia S, Trippler M, Hu Z, Funk E, et al. ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. J Med Virol. 2012; 84(7): 1106-14[DOI][PubMed]
  • 26. Fiorina L, Paolucci S, Papadimitriou S, Baldanti F. Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV. J Virol Methods. 2012; 184(1-2): 103-5[DOI][PubMed]
  • 27. Rembeck K, Waldenstrom J, Hellstrand K, Nilsson S, Nystrom K, Martner A, et al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology. 2014; 59(6): 2131-9[DOI][PubMed]
  • 28. Takahashi H, Mizuta T, Oeda S, Isoda H, Nakashita S, Kawaguchi Y, et al. An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C. J Viral Hepat. 2013; 20(4)-6[DOI][PubMed]
  • 29. Inoue Y, Homma M, Matsuzaki Y, Shibata M, Matsumura T, Ito T, et al. Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood. Antimicrob Agents Chemother. 2004; 48(10): 3813-6[DOI][PubMed]
  • 30. Ackefors M, Gjertsen H, Wernerson A, Weiland O. Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation. J Viral Hepat. 2012; 19(9): 635-9[DOI][PubMed]
  • 31. Brochot E, Castelain S, Duverlie G, Capron D, Nguyen-Khac E, Francois C. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther. 2010; 15(5): 687-95[DOI][PubMed]
  • 32. Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, et al. ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res. 2010; 40(11): 1063-71[DOI][PubMed]
  • 33. Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011; 204(1): 84-93[DOI][PubMed]
  • 34. Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, et al. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol. 2012; 56(2): 313-9[DOI][PubMed]
  • 35. Dai CY, Yu ML, Chuang WL. Association between response to pegylated interferon/ribavirin therapy and ribavirin levels. Hepatology. 2015; 61(1): 408-9[DOI][PubMed]
  • 36. Giusto M, Rodriguez M, Navarro L, Rubin A, Aguilera V, San-Juan F, et al. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. Liver Transpl. 2011; 17(11): 1318-27[DOI][PubMed]
  • 37. Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010; 139(5): 1602-11[DOI][PubMed]
  • 38. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. 2011; 53(2): 389-95[DOI][PubMed]
  • 39. Holmes JA, Roberts SK, Ali RJ, Dore GJ, Sievert W, McCaughan GW, et al. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology. 2014; 59(6): 2152-60[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments